This is a renewal application for the Partnership for Excellence in Cancer Research between The University of Puerto Rico (UPR) and The University of Texas MD Anderson Cancer Center (MDACC). The Partnership proposes structured initiatives to further enhance the research infrastructure within these two institutions to reduce the burden of cancer health disparities. Funds granted in this award will be used to support two full and one pilot research projects. The first full project examines the role of West African ancestry in prostate cancer risk and aggressiveness. Pilot data show an association of several ancestral genetic markers, body mass index, and socioeconomic status with higher-grade prostate cancer. The second full project focuses on magnetic nanoparticle based hyperthermia for ovarian cancer. Pilot project data show a marked decrease in the associated tumor size when treated with nanoparticles. The pilot study is a smoking cessation intervention in oncology clinics. Together, these projects comprise a multidisciplinary research portfolio representing the T l to T3 stages of the translational research continuum. Partnership funds will also be used to: 1) enhance existing collaborations and establish new collaborations; 2) restructure the training pipeline to include customized career development tracks for physicians, scientists and physician scientists interested in cancer medicine to accelerate the development of a critical mass of faculty for the UPR Comprehensive Cancer Center (UPRCCC); 3) implement a cancer education curriculum; and 4) maintain and expand the Outreach Program, including core services and an outreach research project designed to reduce the burden of colorectal cancer among Puerto Ricans. Thus far, the Partnership has established a dynamic collaborative team that is working towards fortifying and stabilizing the developing infrastructure at the UPRCCC as evidenced by a newly constructed UPRCCC Research Center (opened 6/2009); the UPRCCC hospital will be completed in 2016. Funding for a second renewal is critical to cement and build on the substantial momentum and success achieved by the Partnership over the last ten years. The Partnership is poised to fulfill its long-term goal of positioning the UPRCCC to become a frontrunner in addressing health disparities that affect Hispanic populations across the cancer continuum (prevention, early detection, diagnosis, treatment and survivorship).

Public Health Relevance

This renewal seeks to foster and support an existing collaboration between the UPR and MDACC. By addressing differences in incidence, prevalence, mortality, and burden of cancer that exist among Hispanic populations in the US, the Partnership strives to reduce these disparities through efforts in Cancer Research, Training, Education and Outreach. Partnership contributions will also aid in building a stronger national cancer program through the development of a pipeline of well-trained, Hispanic cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA096297-13S2
Application #
9069239
Study Section
Special Emphasis Panel (ZCA1 (O1))
Program Officer
Vallejo-Estrada, Yolanda
Project Start
2002-08-16
Project End
2018-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
13
Fiscal Year
2015
Total Cost
$152,250
Indirect Cost
$50,750
Name
University of Puerto Rico Med Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
948108063
City
San Juan
State
PR
Country
United States
Zip Code
00936
González-Pons, María; Soto-Salgado, Marievelisse; Sevilla, Javier et al. (2018) Seroprevalence of Helicobacter pylori in Hispanics living in Puerto Rico: A population-based study. Helicobacter 23:
Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106
Das, Soma; Parga, Kenia; Chakraborty, Indranil et al. (2018) Magnetic resonance imaging contrast enhancement in vitro and in vivo by octanuclear iron-oxo cluster-based agents. J Inorg Biochem 186:176-186
Thapa, Bibek; Diaz-Diestra, Daysi; Santiago-Medina, Carlene et al. (2018) T1- and T2-weighted Magnetic Resonance Dual Contrast by Single Core Truncated Cubic Iron Oxide Nanoparticles with Abrupt Cellular Internalization and Immune Evasion. ACS Appl Bio Mater 1:79-89
Gonzalez, Velda J; McMillan, Susan; Pedro, Elsa et al. (2018) The Health related Quality of Life of Puerto Ricans during Cancer Treatments; A Pilot Study. P R Health Sci J 37:46-51
Gonzalez, Velda J; Abbas-Aghababazadeh, Farnoosh; Fridley, Brooke L et al. (2018) Expression of Sestrin Genes in Radiotherapy for Prostate Cancer and Its Association With Fatigue: A Proof-of-Concept Study. Biol Res Nurs 20:218-226
Juan-Rivera, Maylein C; Martínez-Ferrer, Magaly (2018) Integrin Inhibitors in Prostate Cancer. Cancers (Basel) 10:
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Gonzalez-Mercado, Velda J; Fridley, Brooke L; Saligan, Leorey N (2018) Sestrin family of genes and their role in cancer-related fatigue. Support Care Cancer 26:2071-2074
Villar-Prados, Alejandro; Wu, Sherry Y; Court, Karem A et al. (2018) Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther :

Showing the most recent 10 out of 157 publications